Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2019 1
2020 3
2021 13
2022 12
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJGT, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz HM, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich HG, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-Tidow C. Denkinger CM, et al. Among authors: tepasse pr. Nat Cancer. 2023 Jan;4(1):96-107. doi: 10.1038/s43018-022-00503-w. Epub 2022 Dec 29. Nat Cancer. 2023. PMID: 36581734 Free PMC article. Clinical Trial.
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, Krist L, Lemhöfer C, Lieb W, Lorenz-Depiereux B, Mikolajczyk R, Montellano FA, Reese JP, Schreiber S, Skoetz N, Störk S, Vehreschild JJ, Witzenrath M, Grill E; NAPKON Study Group. Shi Y, et al. Infection. 2023 Dec;51(6):1679-1694. doi: 10.1007/s15010-023-02043-6. Epub 2023 May 25. Infection. 2023. PMID: 37231313 Free PMC article.
Microvascular dysfunction in COVID-19: the MYSTIC study.
Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse PR, Fobker M, Kühn J, Braune S, Göbel U, Thölking G, Gröschel A, Pavenstädt H, Vink H, Kümpers P. Rovas A, et al. Among authors: tepasse pr. Angiogenesis. 2021 Feb;24(1):145-157. doi: 10.1007/s10456-020-09753-7. Epub 2020 Oct 14. Angiogenesis. 2021. PMID: 33058027 Free PMC article.
Tularemia Presenting Solely with Cervical Lymphadenopathy and Fever.
Boeckel GR, Adiprasito JB, Froböse NJ, Schaumburg F, Vollenberg R, Tepasse PR. Boeckel GR, et al. Among authors: tepasse pr. Diagnostics (Basel). 2022 Aug 18;12(8):2000. doi: 10.3390/diagnostics12082000. Diagnostics (Basel). 2022. PMID: 36010350 Free PMC article.
Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study.
Rovas A, Buscher K, Osiaevi I, Drost CC, Sackarnd J, Tepasse PR, Fobker M, Kühn J, Braune S, Göbel U, Thölking G, Gröschel A, Rossaint J, Vink H, Lukasz A, Pavenstädt H, Kümpers P. Rovas A, et al. Among authors: tepasse pr. Angiogenesis. 2022 Nov;25(4):503-515. doi: 10.1007/s10456-022-09843-8. Epub 2022 Jun 20. Angiogenesis. 2022. PMID: 35723762 Free PMC article.
38 results